Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction

Yıl: 2018 Cilt: 19 Sayı: 5 Sayfa Aralığı: 311 - 318 Metin Dili: İngilizce DOI: 10.14744/AnatolJCardiol.2018.95595

Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction

Öz:
Objective: Although almost half of chronic heart failure (HF) patients have mid-range (HFmrEF) and preserved left-ventricular ejection fraction(HFpEF), no studies have been carried out with these patients in our country. This study aims to determine the demographic characteristics andcurrent status of the clinical background of HFmrEF and HFpEF patients in a multicenter trial.Methods: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction (APOLLON) trial will bean observational, multicenter, and noninterventional study conducted in Turkey. The study population will include 1065 patients from 12 sites inTurkey. All data will be collected at one point in time and the current clinical practice will be evaluated (ClinicalTrials.gov number NCT03026114).Results: We will enroll all consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had New York HeartAssociation class II, III, or IV HF, elevated brain natriuretic peptide levels within the last 30 days, and an left ventricular ejection fraction (LVEF)of at least 40%. Patients fulfilling the exclusion criteria will not be included in the study. Patients will be stratified into two categories accordingto LVEF: mid-range EF (HFmrEF, LVEF 40%-49%) and preserved EF (HFpEF, LVEF ≥50%). Regional quota sampling will be performed to ensure thatthe sample was representative of the Turkish population. Demographic, lifestyle, medical, and therapeutic data will be collected by this specificsurvey.Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF ≥40% and will alsobe the first study to specifically analyze the recently designated HFmrEF category.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Patho-physiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-50. [CrossRef]
  • Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209-16. [CrossRef]
  • Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110: 870-6.
  • Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P, et al. What have we learned about heart failure with midrange ejection fraction one year after its introduction? Eur J Heart Fail 2017; 19: 1569-73. [CrossRef]
  • Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail 2014; 16: 1049-55. [CrossRef]
  • Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ Heart Fail 2017; 10. pii: e003875. [CrossRef]
  • Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-85. [CrossRef]
  • Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol 2017; 106: 359-68. [CrossRef]
  • Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168: 721-30. [CrossRef]
  • Coles AH, Tisminetzky M, Yarzebski J, Lessard D, Gore JM, Darling CE, et al. Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. J Am Heart Assoc 2015; 4. pii: e002303. [CrossRef]
  • Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19: 1258-69. [CrossRef]
  • Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 2016; 4: 464-72. [CrossRef]
  • Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a midrange ejection fraction. Eur J Heart Fail 2017; 19: 1597-605. [CrossRef]
  • 12. Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. JACC Heart Fail 2017; 5: 763-71. [CrossRef]
  • Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017; 19: 1624-34.
  • Eren M, Zoghi M, Tuncer M, Çavuşoğlu Y, Demirbağ R, Şahin M, et al.; TAKTIK Investigators. Turkish registry for diagnosis and treatment of acute heart failur 2016; 44: 637-46. [CrossRef]
  • Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. Turk Kardiyol Dern Ars 2012; 40: 298-308. [CrossRef]
  • Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9. [CrossRef]
  • Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung and blood institute. Circulation 2009; 119: 3070-7. [CrossRef]
  • Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: a 5-year prospective population-based study. Eur Heart J 2008; 29: 339-47. [CrossRef]
  • Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9. [CrossRef]
  • Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design and preliminary data. Am Heart J 2010; 159: 949-55.e1.
  • Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16. [CrossRef]
  • Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of inhospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008; 52: 347- 56. [CrossRef]
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975. [CrossRef]
APA ÖZLEK B, ÖZLEK E, ÇELİK O, CİL C, DOĞAN V, TEKİNALP M, AGUŞ H, KAHRAMAN S, OSKEN A, RENCÜZOĞULLARI İ, TANIK V, BEKAR L, ÇAKIR M, KAYA B, TİBİLLİ H, ÇELİK Y, BAŞARAN Ö, MERT K, SEVİNÇ S, DEMİRCİ E, DONDURMACI E, BİTEKER M (2018). Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction. The Anatolian Journal of Cardiology, 19(5), 311 - 318. 10.14744/AnatolJCardiol.2018.95595
Chicago ÖZLEK Bülent,ÖZLEK Eda,ÇELİK Oğuzhan,CİL Cem,DOĞAN Volkan,TEKİNALP Mehmet,AGUŞ Hicaz Zencirkıran,KAHRAMAN Serkan,OSKEN Altuğ,RENCÜZOĞULLARI İBRAHİM,TANIK Veysel Ozan,BEKAR LÜTFÜ,ÇAKIR MUSTAFA OZAN,KAYA BEDRİ CANER,TİBİLLİ Hakan,ÇELİK Yunus,BAŞARAN Özcan,MERT KADİR UĞUR,SEVİNÇ Samet,DEMİRCİ Erkan,DONDURMACI Engin,BİTEKER MURAT Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction. The Anatolian Journal of Cardiology 19, no.5 (2018): 311 - 318. 10.14744/AnatolJCardiol.2018.95595
MLA ÖZLEK Bülent,ÖZLEK Eda,ÇELİK Oğuzhan,CİL Cem,DOĞAN Volkan,TEKİNALP Mehmet,AGUŞ Hicaz Zencirkıran,KAHRAMAN Serkan,OSKEN Altuğ,RENCÜZOĞULLARI İBRAHİM,TANIK Veysel Ozan,BEKAR LÜTFÜ,ÇAKIR MUSTAFA OZAN,KAYA BEDRİ CANER,TİBİLLİ Hakan,ÇELİK Yunus,BAŞARAN Özcan,MERT KADİR UĞUR,SEVİNÇ Samet,DEMİRCİ Erkan,DONDURMACI Engin,BİTEKER MURAT Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction. The Anatolian Journal of Cardiology, vol.19, no.5, 2018, ss.311 - 318. 10.14744/AnatolJCardiol.2018.95595
AMA ÖZLEK B,ÖZLEK E,ÇELİK O,CİL C,DOĞAN V,TEKİNALP M,AGUŞ H,KAHRAMAN S,OSKEN A,RENCÜZOĞULLARI İ,TANIK V,BEKAR L,ÇAKIR M,KAYA B,TİBİLLİ H,ÇELİK Y,BAŞARAN Ö,MERT K,SEVİNÇ S,DEMİRCİ E,DONDURMACI E,BİTEKER M Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction. The Anatolian Journal of Cardiology. 2018; 19(5): 311 - 318. 10.14744/AnatolJCardiol.2018.95595
Vancouver ÖZLEK B,ÖZLEK E,ÇELİK O,CİL C,DOĞAN V,TEKİNALP M,AGUŞ H,KAHRAMAN S,OSKEN A,RENCÜZOĞULLARI İ,TANIK V,BEKAR L,ÇAKIR M,KAYA B,TİBİLLİ H,ÇELİK Y,BAŞARAN Ö,MERT K,SEVİNÇ S,DEMİRCİ E,DONDURMACI E,BİTEKER M Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction. The Anatolian Journal of Cardiology. 2018; 19(5): 311 - 318. 10.14744/AnatolJCardiol.2018.95595
IEEE ÖZLEK B,ÖZLEK E,ÇELİK O,CİL C,DOĞAN V,TEKİNALP M,AGUŞ H,KAHRAMAN S,OSKEN A,RENCÜZOĞULLARI İ,TANIK V,BEKAR L,ÇAKIR M,KAYA B,TİBİLLİ H,ÇELİK Y,BAŞARAN Ö,MERT K,SEVİNÇ S,DEMİRCİ E,DONDURMACI E,BİTEKER M "Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction." The Anatolian Journal of Cardiology, 19, ss.311 - 318, 2018. 10.14744/AnatolJCardiol.2018.95595
ISNAD ÖZLEK, Bülent vd. "Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction". The Anatolian Journal of Cardiology 19/5 (2018), 311-318. https://doi.org/10.14744/AnatolJCardiol.2018.95595